Notice2025-23824

Hard Empty Capsules From the People's Republic of China: Final Affirmative Determination of Sales at Less Than Fair Value

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published
December 29, 2025

Issuing agencies

Commerce DepartmentInternational Trade Administration

Abstract

The U.S. Department of Commerce (Commerce) determines that hard empty capsules (capsules) from the People's Republic of China (China) are being, or are likely to be, sold in the United States at less than fair value (LTFV) for the period of investigation April 1, 2024, through September 30, 2024.

Full Text

<html>
<head>
<title>Federal Register, Volume 90 Issue 245 (Monday, December 29, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 245 (Monday, December 29, 2025)]
[Notices]
[Pages 60623-60626]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-23824]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration

[A-570-184]


Hard Empty Capsules From the People's Republic of China: Final 
Affirmative Determination of Sales at Less Than Fair Value

AGENCY: Enforcement and Compliance, International Trade Administration, 
Department of Commerce.

SUMMARY: The U.S. Department of Commerce (Commerce) determines that 
hard empty capsules (capsules) from the People's Republic of China 
(China) are being, or are likely to be, sold in the United States at 
less than fair value (LTFV) for the period of investigation April 1, 
2024, through September 30, 2024.

DATES: Applicable December 29, 2025.

FOR FURTHER INFORMATION CONTACT: Rebecca Janz or Jerry Xiao, AD/CVD 
Operations, Office II, Enforcement and Compliance, International Trade 
Administration, U.S. Department of Commerce, 1401 Constitution Avenue 
NW, Washington, DC 20230; telephone: (202) 482-2972 or (202) 482-2273, 
respectively.

SUPPLEMENTARY INFORMATION:

Background

    On May 29, 2025, Commerce published in the Federal Register its 
preliminary affirmative determination in the LTFV investigation of 
capsules from China, in which it also postponed the final determination 
until October 14, 2025.\1\ On August 27, 2025, Commerce issued a post-
preliminary analysis memorandum in which it made certain changes to its 
differential pricing analysis.\2\ We invited interested parties to 
comment on the Preliminary Determination and changes to the 
differential pricing analysis.\3\
---------------------------------------------------------------------------

    \1\ See Hard Empty Capsules from the People's Republic of China: 
Preliminary Affirmative Determination of Sales at Less Than Fair 
Value, Postponement of Final Determination, and Extension of 
Provisional Measures, 90 FR 22704 (May 29, 2025) (Preliminary 
Determination), and accompanying Preliminary Decision Memorandum.
    \2\ See Memorandum, ``Post-Preliminary Analysis for the 
Affirmative Determination in the Less-Than-Fair-Value Investigation 
of Hard Empty Capsules from the People's Republic of China,'' dated 
August 27, 2025 (Post-Preliminary Analysis).
    \3\ See Memorandum, ``Briefing Schedule,'' dated August 28, 
2025.
---------------------------------------------------------------------------

    Due to the lapse in appropriations and Federal Government shutdown, 
on November 14, 2025, Commerce tolled all deadlines in administrative 
proceedings by 47 days.\4\ Additionally, due to a backlog of documents 
that were electronically filed via Enforcement and Compliance's 
Antidumping and Countervailing Duty Centralized Electronic Service 
System (ACCESS) during the Federal Government shutdown, on November 24, 
2025, Commerce tolled all deadlines in administrative proceedings by an 
additional 21 days.\5\ Accordingly, the deadline for this final 
determination is now December 18, 2025.
---------------------------------------------------------------------------

    \4\ See Memorandum, ``Deadlines Affected by the Shutdown of the 
Federal Government,'' dated November 14, 2025.
    \5\ See Memorandum, ``Tolling of all Case Deadlines,'' dated 
November 24, 2025.
---------------------------------------------------------------------------

    A summary of the events that occurred since the Preliminary 
Determination, as well as a full discussion of the issues raised by 
parties for this final determination, may be found in the Issues and 
Decision Memorandum.\6\ The Issues and Decision Memorandum is a public 
document and is on file electronically via ACCESS. ACCESS is available 
to registered users at <a href="https://access.trade.gov">https://access.trade.gov</a>. In addition, a 
complete version of the Issues and Decision Memorandum can be accessed 
directly at <a href="https://access.trade.gov/public/FRNoticesListLayout.aspx">https://access.trade.gov/public/FRNoticesListLayout.aspx</a>.
---------------------------------------------------------------------------

    \6\ See Memorandum, ``Issues and Decision Memorandum for the 
Final Affirmative Determination of Sales at Less Than Fair Value in 
the Investigation of Hard Empty Capsules from the People's Republic 
of China,'' dated concurrently with, and hereby adopted by, this 
notice (Issues and Decision Memorandum).
---------------------------------------------------------------------------

Scope of the Investigation

    The products covered by this investigation are capsules from China. 
For a complete description of the scope of this investigation, see 
Appendix I.

Scope Comments

    In the Preliminary Scope Memorandum, we set aside a period of time 
for parties to raise issues regarding product coverage (i.e., scope) in 
scope-specific case briefs or other written comments.\7\ We received 
scope case and rebuttal briefs from multiple interested parties. For a 
summary of the product coverage comments and rebuttal response 
submitted to the record for this final determination, and accompanying 
discussion and analysis of all comments timely received, see the Final 
Scope Memorandum.\8\ In the Final Scope Memorandum, Commerce determined 
that it is modifying the scope language as it appeared in the 
Initiation Notice.\9\ See Appendix I.
---------------------------------------------------------------------------

    \7\ See Memorandum, ``Less-Than-Fair-Value and Countervailing 
Duty Investigations of Hard Empty Capsules from Brazil, the People's 
Republic of China, India, and the Socialist Republic of Vietnam: 
Scope Comments Decision Memorandum for the Preliminary 
Determination,'' dated March 24, 2025 (Preliminary Scope 
Memorandum).
    \8\ See Memorandum, ``Less-Than-Fair-Value and Countervailing 
Duty Investigations of Hard Empty Capsules from Brazil, the People's 
Republic of China, India, and the Socialist Republic of Vietnam: 
Final Scope Decision Memorandum,'' dated concurrently with this 
notice (Final Scope Memorandum).
    \9\ See Hard Empty Capsules from Brazil, the People's Republic 
of China, India, and the Socialist Republic of Vietnam: Initiation 
of Countervailing Duty Investigations, 89 FR 91680 (November 20, 
2024) (Initiation Notice).
---------------------------------------------------------------------------

Verification

    Commerce conducted verification of the information relied upon in 
making its final determination in this investigation, in accordance 
with section 782(i) of the Tariff Act of 1930, as amended (the Act). 
Specifically, we conducted on-site verifications of the sales and cost 
information submitted by Shandong Healsee Capsule Ltd. (Shandong 
Healsee) and Shanxi JC Biological Technology Co., Ltd. (Shanxi JC) for 
use in our final determination. We used standard verification 
procedures, including an examination of relevant sales and accounting 
records, and original source documents provided by Shandong Healsee and 
Shanxi JC.

Analysis of Comments Received

    All issues raised in the case and rebuttal briefs submitted by 
interested parties in this investigation are addressed in the Issues 
and Decision Memorandum. A list of the issues addressed in the Issues 
and Decision Memorandum is attached to this notice as Appendix II.

Changes Since the Preliminary Determination

    We made certain changes to the margin calculations for Shandong 
Healsee and Shanxi JC since the Preliminary Determination and Post-
Preliminary Analysis. For a discussion of these changes, see the Issues 
and Decision Memorandum.

Separate Rate Companies and the China-Wide Entity

    We preliminarily granted a separate rate to certain respondents 
that we did

[[Page 60624]]

not select for individual examination.\10\ Additionally, because we 
preliminarily did not find that the China-wide entity failed to 
cooperate in this investigation, we preliminarily assigned this same 
rate as the estimate weighted-average dumping margin for the China-wide 
entity.\11\ No party commented on our preliminary separate rate 
determinations or our findings with respect to the China-wide entity. 
Therefore, we continue to find that Shandong Healsee, Shanxi JC, and 
certain non-individually examined companies that are listed in the 
``Final Determination'' rate table below, are eligible for a separate 
rate. We also continue to assign the same rate assigned to the non-
individually examined companies to the China-wide entity.
---------------------------------------------------------------------------

    \10\ See Preliminary Determination, 90 FR at 22705.
    \11\ Id.
---------------------------------------------------------------------------

Combination Rates

    Consistent with the Preliminary Determination and Policy Bulletin 
05.1,\12\ Commerce calculated combination rates for the companies 
eligible for a separate rate.
---------------------------------------------------------------------------

    \12\ See Enforcement and Compliance's Policy Bulletin No. 05.1, 
regarding, ``Separate-Rates Practice and Application of Combination 
Rates in Antidumping Investigations involving Non-Market Economy 
Countries,'' dated April 5, 2005 (Policy Bulletin 05.1), available 
on Commerce's website at <a href="http://enforcement.trade.gov/policy/bull05-1.pdf">http://enforcement.trade.gov/policy/bull05-1.pdf</a>.
---------------------------------------------------------------------------

Final Determination

    Commerce determines that the following estimated weighted-average 
dumping margins exist:
---------------------------------------------------------------------------

    \13\ To determine the cash deposit rate, Commerce normally 
adjusts the estimated weighted-average dumping margin by the amount 
of export subsidies countervailed in a companion countervailing duty 
(CVD) proceeding, when CVD provisional measures are in effect. 
Accordingly, where Commerce has made a final affirmative 
determination for countervailable export subsidies, Commerce offsets 
the estimated weighted-average dumping margin by the appropriate CVD 
rate. However, in the final determination of the companion CVD 
investigation of capsules from China, we found no export subsidies. 
See the unpublished Federal Register notice entitled ``Hard Empty 
Capsules from the People's Republic of China: Final Affirmative 
Countervailing Duty Determination,'' signed and dated concurrently 
with this Federal Register notice. Therefore, Commerce has not 
adjusted the cash deposit rate for export subsidies in the companion 
CVD investigation.
    \14\ Hubei Kornnac Pharmaceutical Co., Ltd. (Hubei Kornnac) 
initially filed a separate rate application under the name ``Hubei 
Humanwell Pharmaceutical Excipients Co., Ltd.'' and subsequently 
notified Commerce that the company's name changed to Hubei Kornnac. 
We preliminarily determined it was appropriate to allow the name 
change. See Preliminary Determination, 90 FR at 22705 n.13. No party 
commented on this determination; thus, we continue to find it is 
appropriate to allow the name change and grant Hubei Kornnac a 
separate rate.
    \15\ In the Preliminary Determination, we listed the name of 
this company as ``Shanxi Guangsheng Medicinal Capsule Co., Ltd. 
A.K.A. Shanxi Guangsheng Capsule Co., Ltd.'' See Preliminary 
Determination, 90 FR at 22706. However, for customs purposes, the 
appropriate marker between a company's name and an ``also known as'' 
name is a semicolon; thus, we are correcting the format of the 
company's names for our final determination.

----------------------------------------------------------------------------------------------------------------
                                                                                                    Cash deposit
                                                                                 Weighted-average       rate
                 Producer                                Exporter                 dumping margin      (percent)
                                                                                     (percent)          \13\
----------------------------------------------------------------------------------------------------------------
Shandong Healsee Capsule Ltd..............  Shandong Healsee Capsule Ltd......               18.71         18.71
Shanxi JC Biological Technology Co., Ltd..  Shanxi JC Biological Technology                   0.00          0.00
                                             Co., Ltd.
Guizhou Guang De Li Pharmaceuticals Co.,    Guizhou Guang De Li                              18.71         18.71
 Ltd.                                        Pharmaceuticals Co., Ltd.
Hebei Kangxin Plant Capsule Co., Ltd......  Hebei Kangxin Plant Capsule Co.,                 18.71         18.71
                                             Ltd.
Hubei Kornnac Pharmaceutical Co., Ltd \14\  Hubei Kornnac Pharmaceutical Co.,                18.71         18.71
                                             Ltd.
Jiangsu Lefan Capsule Co., Ltd............  Jiangsu Lefan Capsule Co., Ltd....               18.71         18.71
Jiujiang Angtai Capsule Co., Ltd..........  Jiujiang Angtai Capsule Co., Ltd..               18.71         18.71
Qingdao Yiqing Biotechnology Co., Ltd.....  Qingdao Yiqing Biotechnology Co.,                18.71         18.71
                                             Ltd.
Shaanxi Genex Bio-Tech Co., Ltd...........  Shaanxi Genex Bio-Tech Co., Ltd...               18.71         18.71
Shanghai Guang De Li Capsule Co., Ltd.....  Shanghai Guang De Li Capsule Co.,                18.71         18.71
                                             Ltd.
Shanxi Guangsheng Medicinal Capsule Co.,    Shanxi Guangsheng Medicinal                      18.71         18.71
 Ltd.; Shanxi Guangsheng Capsule Co., Ltd.   Capsule Co., Ltd.; Shanxi
                                             Guangsheng Capsule Co., Ltd \15\.
Shaoxing Kangke Capsule Co., Ltd..........  Shaoxing Kangke Capsule Co., Ltd..               18.71         18.71
Shaoxing Renhe Capsule Co., Ltd...........  Shaoxing Renhe Capsule Co., Ltd...               18.71         18.71
Xinchang County Hexin Capsule Co., Ltd....  Xinchang County Hexin Capsule Co.,               18.71         18.71
                                             Ltd.
Xinchang County No.6 Capsule Factory......  Xinchang Paulo Import And Export                 18.71         18.71
                                             Co., Ltd.
Shaoxing Kangke Capsule Co., Ltd..........  Xinchang Paulo Import And Export                 18.71         18.71
                                             Co., Ltd.
Zhejiang Huaguang Capsule Co., Ltd........  Xinchang Paulo Import And Export                 18.71         18.71
                                             Co., Ltd.
Shanxi Guangsheng Capsule Co., Ltd........  Xinchang Paulo Import And Export                 18.71         18.71
                                             Co., Ltd.
Zhejiang Pujiang Enerkang Capsule Co., Ltd  Xinchang Paulo Import And Export                 18.71         18.71
                                             Co., Ltd.
Yantai Oriental Pharmacap Co., Ltd........  Yantai Oriental Pharmacap Co., Ltd               18.71         18.71
Ningbo Capsulcn Capsule Co., Ltd..........  Zhejiang Capsulcn Machinery Co.,                 18.71         18.71
                                             Ltd.
Shaoxing Zhongya Capsules Industry Co.,     Zhejiang Capsulcn Machinery Co.,                 18.71         18.71
 Ltd.                                        Ltd.
Shandong Healsee Capsule Ltd..............  Zhejiang Capsulcn Machinery Co.,                 18.71         18.71
                                             Ltd.
Zhejiang Guangjuyuan Biotechnology Co.,     Zhejiang Capsulcn Machinery Co.,                 18.71         18.71
 Ltd.                                        Ltd.
Zhejiang Huaguang Capsule Co., Ltd........  Zhejiang Capsulcn Machinery Co.,                 18.71         18.71
                                             Ltd.
Zhejiang Huaguang Capsule Co., Ltd........  Zhejiang Huaguang Capsule Co., Ltd               18.71         18.71
Zhejiang Huili Capsules Co., Ltd..........  Zhejiang Huili Capsules Co., Ltd..               18.71         18.71
Zhejiang Lujian Capsule Co., Ltd..........  Zhejiang Lujian Capsule Co., Ltd..               18.71         18.71
China-Wide Entity.........................  ..................................               18.71         18.71
----------------------------------------------------------------------------------------------------------------

Disclosure

    Commerce intends to disclose the calculations performed in 
connection with this final determination to interested parties within 
five days of any public announcement or, if there is no public 
announcement, within five days of the date of publication of this 
notice in the Federal Register, in accordance with 19 CFR 351.224(b).

Suspension of Liquidation

    In accordance with section 733(d)(2) of the Act, we instructed U.S. 
Customs and Border Protection (CBP) to suspend liquidation of subject 
merchandise entries, as described in Appendix I of this notice, that 
were entered, or withdrawn from warehouse, for consumption on or after 
May 29, 2025, the date of publication of the Preliminary Determination 
in the Federal Register. In accordance with section 733(d) of the Act, 
we subsequently instructed CBP to discontinue the suspension of

[[Page 60625]]

liquidation of all entries of subject merchandise entered or withdrawn 
from warehouse, on or after November 25, 2025, but to continue the 
suspension of liquidation of all entries of subject merchandise on or 
before November 24, 2025.
    Because the estimated weighted-average dumping margin is zero for 
the Shanxi JC producer/exporter combination, we will discontinue the 
suspension of liquidation and refund all cash deposits already 
collected for this producer/exporter combination, pursuant to section 
735(c)(2) of the Act, and we will exclude merchandise exported and 
produced by Shanxi JC from the antidumping duty order, in the event an 
order is instituted, in accordance with section 735(a)(4) of the Act 
and 19 CFR 351.204(e)(1). However, entries of shipments of subject 
merchandise from Shanxi JC in any other exporter/producer combination, 
or by third parties that sourced subject merchandise from the excluded 
producer/exporter combination, will be subject to suspension of 
liquidation at the China-wide entity rate.
    Other than for entries produced and exported by Shanxi JC, if the 
U.S. International Trade Commission (ITC) issues a final affirmative 
injury determination, we will issue an antidumping duty order, 
reinstate the suspension of liquidation, and require a cash deposit for 
estimated weighted-average antidumping duties, in accordance with 
section 736(a) of the Act, as follows: (1) the cash deposit rate for 
the exporter/producer combinations listed in the table above will be 
the rate identified in the table; (2) for all combinations of Chinese 
exporters/producers of subject merchandise that have not received their 
own separate rate above, the cash deposit rate will be the cash deposit 
rate established for the China-wide entity; and (3) for all non-Chinese 
exporters of subject merchandise that have not received their own 
separate rate above, the cash deposit rate will be the cash deposit 
rate applicable to the Chinese exporter/producer combination that 
supplied that non-Chinese exporter.
    If the ITC determines that material injury, or threat of material 
injury, does not exist, this proceeding will be terminated, and all 
estimated duties deposited or securities posted as a result of the 
suspension of liquidation will be refunded or canceled.

ITC Notification

    In accordance with section 735(d) of the Act, Commerce will notify 
the ITC of its final affirmative determination of sales at LTFV. 
Because Commerce's final determination is affirmative, in accordance 
with section 735(b)(2) of the Act, the ITC will make its final 
determination as to whether the domestic industry in the United States 
is materially injured, or threatened with material injury, by reason of 
imports, or sales (or the likelihood of sales) for importation, of 
capsules no later than 45 days after this final determination. If the 
ITC determines that material injury or threat of material injury does 
not exist, this proceeding will be terminated, all cash deposits will 
be refunded or canceled, and suspension of liquidation will be lifted. 
If the ITC determines that such injury does exist, Commerce will issue 
an antidumping duty order directing CBP to assess, upon further 
instructions by Commerce, antidumping duties on all imports of the 
subject merchandise that are entered, or withdrawn from warehouse, for 
consumption on or after the effective date of the suspension of 
liquidation, as discussed above in the ``Suspension of Liquidation'' 
section above.

Administrative Protective Order (APO)

    This notice serves as the only reminder to parties subject to an 
APO of their responsibility concerning the disposition of proprietary 
information disclosed under APO in accordance with 19 CFR 
351.305(a)(3). Timely written notification of the return or destruction 
of APO materials or conversion to judicial protective order is hereby 
requested. Failure to comply with the regulations and terms of an APO 
is a sanctionable violation.

Notification to Interested Parties

    This final determination is issued and published in accordance with 
sections 735(d) and 777(i) of the Act, and 19 CFR 351.210(c).

    Dated: December 18, 2025.
Christopher Abbott,
Deputy Assistant Secretary for Policy and Negotiations, performing the 
non-exclusive functions and duties of the Assistant Secretary for 
Enforcement and Compliance.

Appendix I

Scope of the Investigation

    The merchandise subject to the scope of the investigation is 
hard empty capsules, which are comprised of two prefabricated, 
hollowed cylindrical sections (cap and body). The cap and body 
pieces each have one closed and rounded end and one open end, and 
are constructed with different or equal diameters at their open 
ends.
    Hard empty capsules are unfilled cylindrical shells composed of 
at least 80 percent by weight of a water soluble polymer that is 
considered non-toxic and appropriate for human or animal consumption 
by the United States Pharmacopeia--National Formulary (USP-NF), Food 
Chemical Codex (FCC), or equivalent standards. The most common 
polymer materials in hard empty capsules are gelatin derived from 
animal collagen (including, but not limited to, pig, cow, or fish 
collagen), hydroxypropyl methylcellulose (HPMC), and pullulan.
    Hard empty capsules may also contain water and additives, such 
as opacifiers, colorants, processing aids, controlled release 
agents, plasticizers, and preservatives. Hard empty capsules may 
also be imprinted or otherwise decorated with markings.
    Hard empty capsules are covered by the scope of the 
investigation regardless of polymer material, additives, 
transparency, opacity, color, imprinting, or other markings.
    Hard empty capsules are also covered by the scope of the 
investigation regardless of their size, weight, length, diameter, 
thickness, and filling capacity.
    Cap and body pieces of hard empty capsules are covered by the 
scope of the investigation regardless of whether they are imported 
together or separately, and regardless of whether they are imported 
in attached or detached form.
    Hard empty capsules covered by the scope of the investigation 
are those that disintegrate in water, simulated intestinal fluid, 
simulated gastric fluid, or other similar water-based (i.e., 
aqueous) fluids within 2 hours under tests specified in Chapter 701 
of the USP-NF, or equivalent disintegration tests.
    Hard empty capsules are classifiable under subheadings 
9602.00.1040 and 9602.00.5010 of the Harmonized Tariff Schedule of 
the United States (HTSUS). In addition, hard empty capsules may be 
imported under HTSUS subheading 1905.90.9090; gelatin hard empty 
capsules may be imported under HTSUS subheading 3503.00.5510; HPMC 
hard empty capsules may be imported under HTSUS subheading 
3923.90.0080; and pullulan hard empty capsules may be imported under 
HTSUS subheading 2106.90.9998. Although the HTSUS subheadings are 
provided for convenience and customs purposes, the written 
description of the merchandise covered by the investigation is 
dispositive.

Appendix II

List of Topics Discussed in the Issues and Decision Memorandum

I. Summary
II. Background
III. Changes Since the Preliminary Determination
IV. Application of Facts Available (AFA) and Use of Adverse 
Inference
V. Discussion of the Issues
    Comment 1: Application of AFA to Shandong Healsee's U.S. 
Expenses
    Comment 2: Whether to Collapse Shandong Healsee with Its 
Affiliated Input Suppliers
    Comment 3: Application of AFA to Shanxi JC
    Comment 4: Whether to Include Freight Expenses in the 
Calculation of Shanxi JC's By-Product Input Costs
    Comment 5: The Appropriate Short-Term Interest Rate for the 
Calculation of

[[Page 60626]]

Shanxi JC's Credit Expenses and Inventory Carrying Costs
    Comment 6: Whether the Turkish Starch Surrogate Value is 
Aberrational
    Comment 7: Selection of the Primary Surrogate Country
    Comment 8: Selection of Surrogate Financial Statements
    Comment 9: Differential Pricing Test
VI. Recommendation

[FR Doc. 2025-23824 Filed 12-23-25; 8:45 am]
BILLING CODE 3510-DS-P


</pre></body>
</html>
Indexed from Federal Register on December 29, 2025.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.